The Role of Pharmacoepidemiology in Regulatory Agencies

Pharmacoepidemiology, Fifth Edition

Volumn , Issue , 2012, Pages 107-116

  Pan, Gerald J Dal ^a   Arlett, Peter ^b  

^a CENTER FOR DRUG EVALUATION AND RESEARCH   (United States)

^b EUROPEAN MEDICINES AGENCY   (United Kingdom)

Author keywords

Drug safety; Evidence based decision making; Regulatory agency

Indexed keywords

EID: 84883152757     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1002/9781119959946.ch8     Document Type: Chapter

References (28)

1. Braun MM, Farag-El-Massah S, Xu K, Cote TR. Emergence of orphan drugs in the United States; a quantitative assessment of the fi rst 25 years. Nat Rev Drug Discov 2010; 9: 519-22.
2. European Medicines Agency. Orphan Designation. http://www.ema.europa.eu/ema/index.jsp?curl=pages/ regulation/general/general_content_000029.jspand murl=menus/regulations/regulations.jspandmid=WC0 b01ac05800240ce andjsenabled=true (accessed June 2011).
3. Schieppati A, Henter JI, Daina E, Aperia A. Why rare diseases are an important medical and social issue. Lancet 2008; 371: 2039-41.
4. 21CFR314. Code of Federal Regulations Title 21, 314.510. Approval based on a surrogate endpoint or on an effect on a clinical endpoint other than survival or irreversible morbidity.
5. Commission Regulation (EC) No 507/2006 of 29 March 2006 on the conditional marketing authorisation for medicinal products for human: http://ec. europa.eu/health/documents/eudralex/vol-1/index_ en.htm (accessed June 2011).
6. McKee AE, Farrell AT, Pazdur R, Woodcock J. The role of the US Food and Drug Administration review process: Clinical trials endpoints in oncology. Oncologist 2010; 15 (Suppl 1): 13-18.
7. US Department of Health and Human Services. Food and Drug Administration. Guidance for Industry: Diabetes Mellitus - Evaluating Cardiovascular Risk in New Anitdiabetic Therapies to Treat Type 2 Diabetes, December 2008.
8. Volume 9A - Pharmacovigilance for Medicinal Products for Human Use, Part I.3. http://ec.europa.eu/health/ documents/eudralex/vol-9/index_en.htm (accessed June 2011).
9. McMahon AW, Pratt RG, Hammad TA, Kozlowski S, Zhou E, Lu S, et al. Description of hypersensitivity adverse events following administration of heparin that was potentially contaminated with oversulfated chondroitin sulfate in early 2008. Pharmacoepidemiol Drug Saf 2010; 19: 921-33.
10. Kaplan S, Staffa JA, Dal Pan GJ. Duration of therapy with metoclopramide: a prescription claims data study. Pharmacoepidemiol Drug Saf 2007; 16: 878-81.
11. FDA. FDA Requires Boxed Warning and Risk Mitigation Strategy for Metoclopramide -Containing Drugs Agency warns against chronic use of these products to treat gastrointestinal disorders, Feb. 26, 2009. http://www.fda.gov/NewsEvents/Newsroom/Press Announcements/2009/ucm149533.htm (accessed June 2011).
12. Bower WA, Johns M, Margolis HS, Williams IT, Bell BP. Population-based surveillance for acute liver failure. Am J Gastroenterol 2007; 102: 2459-63.
13. ®)-associated overdoses in the United States. Pharmacoepidemiol Drug Saf 2006; 15: 398-405.
14. Hawton K, Townsend E, Deeks J, Appleby L, Gunnell D, Bennewith O, et al. Effects of legislation restricting pack sizes of paracetamol and salicylate on self poising in the United Kingdom: before and after study. BMJ 2001; 322: 107.
15. Department of Health and Human Services. Food and Drug Administration. Prescription drug products containing acetaminophen; actions to reduce liver injury from unintentional overuse. Fed Regist 2011; 76: 2691-7.
16. US Department of Health and Human Services. Food and Drug Administration. Guidance for Industry: Development and Use of Risk Minimization Action Plans, March, 2005.
17. Wysowski DK, Bacsanyi J. Cisapride and fatal arrhythmia. N Engl J Med 1996; 335: 290-1.
18. Smalley W, Shatin D, Wysowski DK, Gurwitz J, Andrade SE, Goodman M, et al. Contraindicated Use of Cisapride: Impact of Food and Drug Administration Regulatory Action. JAMA 2000; 284: 3036-9.
19. Weatherby LB, Nordstrom BL, Fife D, Walker AM. The impact of wording in "Dear doctor " letters and in black box labels. Clin Pharmacol Ther 2002; 72: 735-42.
20. Rawlins M. De Testimonio: on the evidence for decisions about the use of therapeutic interventions. Lancet 2008; 372: 2152-61.
21. van Staa TP, Smeeth L, Persson I, Parkinson J, Leufkens HG. Evaluating drug toxicity signals: is a hierarchical classifi cation of evidence useful or harmful? Pharmacoepidemiol Drug Saf 2008; 17: 475-84.
22. European Network of Centres for Pharmacoepidemiology and Pharmacovigilance. www.encepp.eu (accessed June 2011).
23. European Network of Centres for Pharmacoepidemiology and Pharmacovigilance. Electronic Register of Studies. http://www.encepp.eu/encepp/studiesDatabase. jsp (accessed June 2011).
24. Department of Health and Human Services. US Food and Drug Administration. PDUFA IV Reauthori zation Performance Goals and Procedures; Fiscal Years 2008 through 2012. http://www.fda.gov/ForIndustry/UserFees /PrescriptionDrugUserFee/ucm119243.htm (accessed June 2011).
25. Strom BL, Carson JL, Halpern AC, Schinnar R, Snyder ES, Stolley PD, et al. Using a claims database to investigate drug -induced Stevens -Johnson syndrome. Stat Med 1991; 10: 565-76.
26. Pharmacoepidemiological Research on Outcomes of Therapeutics by a European Consortium. http:// www.imi -protect.eu/index.html (accessed June 2011).
27. Agency for Healthcare Research and Quality. CERTs Overview. http://certs.hhs.gov/about/certsovr.htm (accessed June 2011).
28. US Department of Health and Human Services. US Food and Drug Administration. The Sentinel Initiative - National Strategy for Monitoring Medical Product Safety, May 2008. http://www.fda.gov/downloads/Safety/FDAsSentinelInitiative/UCM124701.pdf(accessed June 2011).